Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome

NCT04205838 is registered in ClinicalTrials.gov with Jonsson Comprehensive Cancer Center as lead sponsor.

NCT NCT04205838
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04205838 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
IL-1 Receptor Antagonist to Prevent Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome
Lead sponsor
Jonsson Comprehensive Cancer Center
Phase
Phase 2
Overall status
Terminated
Start date
March 4, 2020
Completion date
February 19, 2026
Enrollment
23 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, not otherwise specified, high grade b-cell lymphoma, progressive disease, recurrent diffuse large b-cell lymphoma, recurrent high grade b-cell lymphoma, recurrent primary mediastinal (thymic) large b-cell cell lymphoma, recurrent transformed follicular lymphoma to diffuse large b-cell lymphoma, refractory diffuse large b-cell lymphoma, refractory high grade b-cell lymphoma, refractory primary mediastinal (thymic) large b-cell cell lymphoma, refractory transformed follicular lymphoma to diffuse large b-cell lymphoma